• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

先天性纤维蛋白原异常伴反复血栓形成。

Congenital fibrinogen disorders with repeated thrombosis.

机构信息

Division of Blood Vessel Surgery, The First Affiliated Hospital of Zhengzhou University, No. 1 of Jianshe East Road, Zhengzhou, 450052, China.

出版信息

J Thromb Thrombolysis. 2020 Feb;49(2):312-315. doi: 10.1007/s11239-019-01958-y.

DOI:10.1007/s11239-019-01958-y
PMID:31542854
Abstract

Congenital dysfibrinogenemia is characterized with undetectable or low fibrinogen level by Clauss assay complicated by bleeding and/or thrombosis. These may lead to a diagnostic problem to some clinicians unfamiliar with this disease. We reported a case of congenital dysfibrinogenemia manifested as hemorrhage, repeated thrombosis, low fibrinogen levels through Clauss assay and but normal levels of fibrinogen through PT-derived tests. In conclusion, to patients with thrombosis complicated by decreased fibrinogen level, clinicians and laboratory physicians should be alert to the possibility of congenital dysfibrinogenemia.

摘要

先天性纤维蛋白原血症的特征是 Clauss 测定法检测到的纤维蛋白原水平极低或无法检测到,伴有出血和/或血栓形成。对于不熟悉这种疾病的临床医生来说,这可能会导致诊断问题。我们报告了一例先天性纤维蛋白原血症病例,表现为出血、反复血栓形成、Clauss 测定法纤维蛋白原水平降低,但 PT 衍生试验纤维蛋白原水平正常。总之,对于伴有纤维蛋白原水平降低的血栓形成患者,临床医生和实验室医生应警惕先天性纤维蛋白原血症的可能性。

相似文献

1
Congenital fibrinogen disorders with repeated thrombosis.先天性纤维蛋白原异常伴反复血栓形成。
J Thromb Thrombolysis. 2020 Feb;49(2):312-315. doi: 10.1007/s11239-019-01958-y.
2
Combined use of Clauss and prothrombin time-derived methods for determining fibrinogen concentrations: Screening for congenital dysfibrinogenemia.联合使用Clauss法和凝血酶原时间衍生法测定纤维蛋白原浓度:先天性异常纤维蛋白原血症的筛查
J Clin Lab Anal. 2018 May;32(4):e22322. doi: 10.1002/jcla.22322. Epub 2017 Sep 18.
3
Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management.纤维蛋白原血症:从分子异常到临床表现和治疗。
J Thromb Haemost. 2015 Jun;13(6):909-19. doi: 10.1111/jth.12916. Epub 2015 May 2.
4
Screening method for congenital dysfibrinogenemia using clot waveform analysis with the Clauss method.应用 Clauss 法的血栓波形分析对先天性纤维蛋白原异常血症进行筛查的方法。
Int J Lab Hematol. 2021 Apr;43(2):281-289. doi: 10.1111/ijlh.13358. Epub 2020 Oct 8.
5
Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia.在纤维蛋白原异常血症患者中比较 Clauss 法纤维蛋白原测定和基于凝血酶原时间的纤维蛋白原检测方法。
Thromb Res. 2010 Dec;126(6):e428-33. doi: 10.1016/j.thromres.2010.09.004. Epub 2010 Oct 13.
6
Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen.家族性异常纤维蛋白原血症与血栓形成倾向。纤维蛋白原问题SSC小组委员会的一项研究报告。
Thromb Haemost. 1995 Jan;73(1):151-61.
7
Risk of bleeding and thrombosis in inherited qualitative fibrinogen disorders.遗传性定性纤维蛋白原疾病的出血和血栓形成风险。
Eur J Haematol. 2019 Oct;103(4):379-384. doi: 10.1111/ejh.13296. Epub 2019 Aug 1.
8
Use of Fibrinogen Determination Methods in Differential Diagnosis of Hypofibrinogenemia and Dysfibrinogenemia.纤维蛋白原测定方法在低纤维蛋白原血症和异常纤维蛋白原血症鉴别诊断中的应用
Clin Lab. 2021 Apr 1;67(4). doi: 10.7754/Clin.Lab.2020.200820.
9
Two novel mutations in the fibrinogen γ nodule.纤维蛋白原γ 节中的两个新突变。
Thromb Res. 2014 Oct;134(4):901-8. doi: 10.1016/j.thromres.2014.07.021. Epub 2014 Jul 21.
10
The amplitude of coagulation curves from thrombin time tests allows dysfibrinogenemia caused by the common mutation FGG-Arg301 to be distinguished from hypofibrinogenemia.凝血酶时间测试所得凝血曲线的幅度,可将常见突变FGG-Arg301引起的异常纤维蛋白原血症与低纤维蛋白原血症区分开来。
Int J Lab Hematol. 2017 Jun;39(3):301-307. doi: 10.1111/ijlh.12625. Epub 2017 Mar 20.

引用本文的文献

1
A Quest to Find the Aetiology of Pulmonary Embolism Beyond the Common: A Case of Dyshypofibrinogenemia Presenting as Pulmonary Embolism.探寻肺栓塞常见病因之外的病因:一例以肺栓塞形式呈现的低纤维蛋白原血症病例
Cureus. 2023 Apr 16;15(4):e37647. doi: 10.7759/cureus.37647. eCollection 2023 Apr.
2
Control of Blood Coagulation by Hemocompatible Material Surfaces-A Review.血液相容性材料表面对血液凝固的控制——综述
Bioengineering (Basel). 2021 Dec 15;8(12):215. doi: 10.3390/bioengineering8120215.
3
Congenital Afibrinogenemia and Hypofibrinogenemia: Laboratory and Genetic Testing in Rare Bleeding Disorders with Life-Threatening Clinical Manifestations and Challenging Management.

本文引用的文献

1
Identification of novel mutations in congenital afibrinogenemia patients and molecular modeling of missense mutations in Pakistani population.先天性无纤维蛋白原血症患者新突变的鉴定及巴基斯坦人群错义突变的分子建模
Thromb J. 2017 Sep 12;15:24. doi: 10.1186/s12959-017-0143-3. eCollection 2017.
2
Severe Thrombotic Complications in Congenital Afibrinogenemia: A Pathophysiological and Management Dilemma.先天性无纤维蛋白原血症的严重血栓并发症:病理生理学与管理困境
Semin Thromb Hemost. 2016 Jul;42(5):577-82. doi: 10.1055/s-0036-1581103. Epub 2016 Jun 2.
3
Laboratory and Genetic Investigation of Mutations Accounting for Congenital Fibrinogen Disorders.
先天性无纤维蛋白原血症和低纤维蛋白原血症:危及生命的临床表现和具有挑战性管理的罕见出血性疾病的实验室和基因检测
Diagnostics (Basel). 2021 Nov 19;11(11):2140. doi: 10.3390/diagnostics11112140.
先天性纤维蛋白原异常相关突变的实验室及遗传学研究
Semin Thromb Hemost. 2016 Jun;42(4):356-65. doi: 10.1055/s-0036-1571340. Epub 2016 Mar 28.
4
Clinical features and molecular basis of 102 Chinese patients with congenital dysfibrinogenemia.102例中国先天性纤维蛋白原异常血症患者的临床特征及分子基础
Blood Cells Mol Dis. 2015 Dec;55(4):308-15. doi: 10.1016/j.bcmd.2015.06.002. Epub 2015 Jun 14.
5
Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: Identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation.7 名纤维蛋白原功能异常或纤维蛋白原减少症患者的分子特征:在纤维蛋白原 Bβ链中发现导致糖基化增加的新突变。
Thromb Res. 2015 Jul;136(1):168-74. doi: 10.1016/j.thromres.2015.05.007. Epub 2015 May 14.
6
Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management.纤维蛋白原血症:从分子异常到临床表现和治疗。
J Thromb Haemost. 2015 Jun;13(6):909-19. doi: 10.1111/jth.12916. Epub 2015 May 2.
7
Natural history of patients with congenital dysfibrinogenemia.先天性纤维蛋白原异常血症患者的自然病史。
Blood. 2015 Jan 15;125(3):553-61. doi: 10.1182/blood-2014-06-582866. Epub 2014 Oct 15.
8
Fibrinolysis and the control of blood coagulation.纤维蛋白溶解与血液凝固的控制
Blood Rev. 2015 Jan;29(1):17-24. doi: 10.1016/j.blre.2014.09.003. Epub 2014 Sep 16.
9
Two novel mutations in the fibrinogen γ nodule.纤维蛋白原γ 节中的两个新突变。
Thromb Res. 2014 Oct;134(4):901-8. doi: 10.1016/j.thromres.2014.07.021. Epub 2014 Jul 21.
10
Congenital fibrinogen disorders: an update.先天性纤维蛋白原异常:更新。
Semin Thromb Hemost. 2013 Sep;39(6):585-95. doi: 10.1055/s-0033-1349222. Epub 2013 Jul 12.